William C Shakespeare
Overview
Explore the profile of William C Shakespeare including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1931
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang W, Li F, Gong Y, Zhang Y, Youngsaye W, Xu Y, et al.
Bioorg Med Chem Lett
. 2022 Nov;
80:129084.
PMID: 36423823
In the treatment of non-small cell lung cancer (NSCLC), patients harboring exon 20 insertion mutations in the epidermal growth factor receptor (EGFR) gene (EGFR) have few effective therapies because this...
2.
Gonzalvez F, Vincent S, Baker T, Gould A, Li S, Wardwell S, et al.
Cancer Discov
. 2021 Feb;
11(7):1672-1687.
PMID: 33632773
Most exon 20 insertion (ex20ins) driver mutations in non-small cell lung cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To address the limitations of existing therapies targeting...
3.
Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, et al.
Clin Cancer Res
. 2016 Nov;
22(22):5527-5538.
PMID: 27780853
Purpose: Non-small cell lung cancers (NSCLCs) harboring ALK gene rearrangements (ALK) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) crizotinib through development of secondary...
4.
Huang W, Liu S, Zou D, Thomas M, Wang Y, Zhou T, et al.
J Med Chem
. 2016 May;
59(10):4948-64.
PMID: 27144831
In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance...
5.
Zech S, Kohlmann A, Zhou T, Li F, Squillace R, Parillon L, et al.
J Med Chem
. 2015 Dec;
59(2):671-86.
PMID: 26700752
Choline kinase α (ChoKα) is an enzyme involved in the synthesis of phospholipids and thereby plays key roles in regulation of cell proliferation, oncogenic transformation, and human carcinogenesis. Since several...
6.
Kohlmann A, Zech S, Li F, Zhou T, Squillace R, Commodore L, et al.
J Med Chem
. 2013 Jan;
56(3):1023-40.
PMID: 23302067
Lactate dehydrogenase A (LDH-A) catalyzes the interconversion of lactate and pyruvate in the glycolysis pathway. Cancer cells rely heavily on glycolysis instead of oxidative phosphorylation to generate ATP, a phenomenon...
7.
Gozgit J, Wong M, Moran L, Wardwell S, Mohemmad Q, Narasimhan N, et al.
Mol Cancer Ther
. 2012 Jan;
11(3):690-9.
PMID: 22238366
Members of the fibroblast growth factor receptor family of kinases (FGFR1-4) are dysregulated in multiple cancers. Ponatinib (AP24534) is an oral multitargeted tyrosine kinase inhibitor being explored in a pivotal...
8.
Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell S, et al.
Chem Biol Drug Des
. 2011 Nov;
78(6):999-1005.
PMID: 22034911
Activating gene rearrangements of anaplastic lymphoma kinase (ALK) have been identified as driver mutations in non-small-cell lung cancer, inflammatory myofibroblastic tumors, and other cancers. Crizotinib, a dual MET/ALK inhibitor, has...
9.
Thomas M, Huang W, Wen D, Zhu X, Wang Y, Metcalf C, et al.
Bioorg Med Chem Lett
. 2011 May;
21(12):3743-8.
PMID: 21561767
Ponatinib (AP24534) was previously identified as a pan-BCR-ABL inhibitor that potently inhibits the T315I gatekeeper mutant, and has advanced into clinical development for the treatment of refractory or resistant CML....
10.
Katayama R, Khan T, Benes C, Lifshits E, Ebi H, Rivera V, et al.
Proc Natl Acad Sci U S A
. 2011 Apr;
108(18):7535-40.
PMID: 21502504
The echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a molecular target in a small subset of non-small cell lung cancers (NSCLCs). This fusion leads to constitutive...